Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 17,200 shares, a growth of 25.5% from the January 31st total of 13,700 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 33,700 shares, the short-interest ratio is currently 0.5 days.

Insiders Place Their Bets

In related news, Director Michael Houghton purchased 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the acquisition, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently made changes to their positions in ASMB. JPMorgan Chase & Co. increased its position in Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 3,442 shares during the period. Palumbo Wealth Management LLC bought a new stake in shares of Assembly Biosciences during the fourth quarter valued at about $180,000. Marshall Wace LLP lifted its holdings in Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 2,098 shares during the period. FMR LLC grew its position in Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares in the last quarter. Finally, Man Group plc acquired a new position in Assembly Biosciences during the 4th quarter valued at about $309,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Assembly Biosciences Price Performance

ASMB opened at $11.43 on Friday. Assembly Biosciences has a 1 year low of $11.23 and a 1 year high of $19.93. The company’s 50 day simple moving average is $14.14 and its 200 day simple moving average is $15.50.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.